New Russian tenders for orphan disease drugs include ones originated by Roche and Shire
The Russian Ministry of Health has summed up the results of the first 10 tenders for the supply of drugs against five orphan diseases within the Seven Nosologies state program, a program which involves purchases of the most expensive drugs for state needs, according to press-service of the Ministry, reports The Pharma Letter’s local correspondent.
Pharmstandard, a Russian leading drugmaker and the largest operator of state orders under Seven Nosologies became a winner of two of these tenders for the sum of 446.1 million roubles ($6.8 million).
In accordance with the first tender, the company will supply tocilizumab, which is a drug, used in the treatment of juvenile arthritis. In Russia, it is represented by the Actemra brand of Swiss pharma giant Roche (ROG: SIX).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze